ea0013oc8 | Clinical and translational endocrinology | SFEBES2007
Eastell Richard
, Black Dennis
, Cauley Jane
, Cosman Felicia
, Cummings Steve
, Delmas Pierre
, Eriksen Erik Fink
, Fraser William
, Hue Trisha
, Lakatos Peter
, Leung Ping-Chung
, Man Zulema
, McLellan Alastair
, Mesenbrink Peter
, Reid David M
, Reid Ian
, Boonen Steven
Objectives and methods: The HORIZON-PFT is a multinational, 3-year, randomized, double-blind, placebo-controlled trial evaluating the potential of once-yearly zoledronic acid (ZOL) 5 mg, infused over 15 minutes, to decrease risk of fracture in 7736 postmenopausal osteoporotic women 6589 years of age.Results: Treatment with ZOL 5 mg resulted in significant relative risk reductions in morphometric vertebral fracture of 70% vs PBO (3.8% vs 12.8%; 95% ...